Cargando…

Physiologically-Based Pharmacokinetic Modeling Characterizes the CYP3A-Mediated Drug-Drug Interaction Between Fluconazole and Sildenafil in Infants

Physiologically-based pharmacokinetic (PBPK) modeling can potentially predict pediatric drug-drug interactions (DDIs) when clinical DDI data are limited. In infants for whom treatment of pulmonary hypertension and prevention or treatment of invasive candidiasis are indicated, sildenafil with flucona...

Descripción completa

Detalles Bibliográficos
Autores principales:	Salerno, Sara N., Edginton, Andrea, Gerhart, Jacqueline G., Laughon, Matthew M., Ambalavanan, Namasivayam, Sokol, Gregory M., Hornik, Chi D., Stewart, Dan, Mills, Mary, Martz, Karen, Gonzalez, Daniel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8138939/ https://www.ncbi.nlm.nih.gov/pubmed/32691891 http://dx.doi.org/10.1002/cpt.1990

Ejemplares similares

Safety of sildenafil in extremely premature infants: a phase I trial
por: Jackson, Wesley, et al.
Publicado: (2021)

Physiologically‐Based Pharmacokinetic Modeling of Fluconazole Using Plasma and Cerebrospinal Fluid Samples From Preterm and Term Infants
por: Gerhart, Jacqueline G., et al.
Publicado: (2019)

Safety of sildenafil in premature infants at risk of bronchopulmonary dysplasia: Rationale and methods of a phase II randomized trial
por: Lang, Jason E., et al.
Publicado: (2022)

Characterizing Pharmacokinetics in Children With Obesity—Physiological, Drug, Patient, and Methodological Considerations
por: Gerhart, Jacqueline G., et al.
Publicado: (2022)

An opportunistic study evaluating pharmacokinetics of sildenafil for the treatment of pulmonary hypertension in infants
por: Thakkar, Nilay, et al.
Publicado: (2016)

Sildenafil and Retinopathy of Prematurity Risk in Very Low Birth Weight Infants
por: Samiee-Zafarghandy, Samira, et al.
Publicado: (2015)

Physiologically Based Pharmacokinetic Modeling and Simulation in Pediatric Drug Development
por: Maharaj, A R, et al.
Publicado: (2014)

Physiologically Based Pharmacokinetic Approach to Determine Dosing on Extracorporeal Life Support: Fluconazole in Children on ECMO
por: Watt, Kevin M., et al.
Publicado: (2018)

Development of an Adult Physiologically Based Pharmacokinetic Model of Solithromycin in Plasma and Epithelial Lining Fluid
por: Salerno, Sara N., et al.
Publicado: (2017)

Use of Real‐World Data and Physiologically‐Based Pharmacokinetic Modeling to Characterize Enoxaparin Disposition in Children With Obesity
por: Gerhart, Jacqueline G., et al.
Publicado: (2022)

Development and Evaluation of a Virtual Population of Children with Obesity for Physiologically Based Pharmacokinetic Modeling
por: Gerhart, Jacqueline G., et al.
Publicado: (2021)

Safety of sildenafil in premature infants with severe bronchopulmonary dysplasia (SILDI-SAFE): a multicenter, randomized, placebo-controlled, sequential dose-escalating, double-masked, safety study
por: Schneider, Simone, et al.
Publicado: (2020)

Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats
por: Lou, Yutao, et al.
Publicado: (2023)

Physiologically based pharmacokinetic modeling of tacrolimus for food–drug and CYP3A drug–drug–gene interaction predictions
por: Loer, Helena Leonie Hanae, et al.
Publicado: (2023)

Pharmacokinetics of the CYP3A4 and CYP2B6 Inducer Carbamazepine and Its Drug–Drug Interaction Potential: A Physiologically Based Pharmacokinetic Modeling Approach
por: Fuhr, Laura Maria, et al.
Publicado: (2021)

Physiologically‐Based Pharmacokinetic Modeling for the Prediction of CYP2D6‐Mediated Gene–Drug–Drug Interactions
por: Storelli, Flavia, et al.
Publicado: (2019)

Physiologically‐based pharmacokinetic modeling to predict CYP3A4‐mediated drug‐drug interactions of finerenone
por: Wendl, Thomas, et al.
Publicado: (2021)

The Effect of Liver and Kidney Disease on the Pharmacokinetics of Clozapine and Sildenafil: A Physiologically Based Pharmacokinetic Modeling
por: Ghoneim, Amira M, et al.
Publicado: (2020)

Physiologically‐based pharmacokinetic modeling to predict drug interactions of lemborexant with CYP3A inhibitors
por: Ueno, Takashi, et al.
Publicado: (2021)

Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects
por: Gardin, Anne, et al.
Publicado: (2018)

Evaluation of Pharmacokinetic and Pharmacodynamic Drug–Drug Interaction of Sacubitril/Valsartan (LCZ696) and Sildenafil in Patients With Mild‐to‐Moderate Hypertension
por: Hsiao, H‐L, et al.
Publicado: (2017)

A Physiologically Based Pharmacokinetic and Pharmacodynamic Model of the CYP3A4 Substrate Felodipine for Drug–Drug Interaction Modeling
por: Fuhr, Laura Maria, et al.
Publicado: (2022)

Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates
por: Otsuka, Yukio, et al.
Publicado: (2023)

Structural Characterization of CYP51 from Trypanosoma cruzi and Trypanosoma brucei Bound to the Antifungal Drugs Posaconazole and Fluconazole
por: Chen, Chiung-Kuang, et al.
Publicado: (2010)

Fluconazole Induced Fixed Drug Eruption
por: Kim, Chi Yeon, et al.
Publicado: (2011)

Tacrolimus pharmacokinetics are influenced by CYP3A5, age, and concomitant fluconazole in pediatric kidney transplant patients
por: Alghamdi, Alaa, et al.
Publicado: (2023)

Physiologically‐based pharmacokinetic modeling of quinidine to establish a CYP3A4, P‐gp, and CYP2D6 drug–drug–gene interaction network
por: Feick, Denise, et al.
Publicado: (2023)

Physiologically Based Pharmacokinetic Modeling of Bupropion and Its Metabolites in a CYP2B6 Drug-Drug-Gene Interaction Network
por: Marok, Fatima Zahra, et al.
Publicado: (2021)

Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators
por: Ngo, Lien Thi, et al.
Publicado: (2023)

Herb-Drug Interaction of Epimedium sagittatum (Sieb. et Zucc.) Maxim Extract on the Pharmacokinetics of Sildenafil in Rats
por: Hsueh, Thomas Y., et al.
Publicado: (2013)

Pharmacokinetic and Pharmacodynamic Comparison of Sildenafil‐Bosentan and Sildenafil‐Ambrisentan Combination Therapies for Pulmonary Hypertension
por: Hakamata, A, et al.
Publicado: (2016)

Changes in CYP3A4 Enzyme Expression and Biochemical Markers Under Acute Hypoxia Affect the Pharmacokinetics of Sildenafil
por: Zhang, Juanhong, et al.
Publicado: (2022)

Physiologically‐Based Pharmacokinetic Modeling vs. Allometric Scaling for the Prediction of Infliximab Pharmacokinetics in Pediatric Patients
por: Malik, Paul R. V., et al.
Publicado: (2019)

Using Physiologically Based Pharmacokinetic Modeling for Mechanistic Insight: Cases of Reverse Translation
por: Edginton, Andrea N.
Publicado: (2017)

In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics
por: Jin, Yi, et al.
Publicado: (2017)

Fixed Drug Eruption Caused by Sildenafil Citrate
por: Choi, Sun Young, et al.
Publicado: (2017)

Prediction of Drug-Drug Interactions with Bupropion and Its Metabolites as CYP2D6 Inhibitors Using a Physiologically-Based Pharmacokinetic Model
por: Xue, Caifu, et al.
Publicado: (2017)

Use of physiologically‐based pharmacokinetic modeling to inform dosing of the opioid analgesics fentanyl and methadone in children with obesity
por: Gerhart, Jacqueline G., et al.
Publicado: (2022)

Physiologically Based Pharmacokinetic (PBPK) Modeling of Clopidogrel and Its Four Relevant Metabolites for CYP2B6, CYP2C8, CYP2C19, and CYP3A4 Drug–Drug–Gene Interaction Predictions
por: Loer, Helena Leonie Hanae, et al.
Publicado: (2022)

Dynamically simulating the interaction of midazolam and the CYP3A4 inhibitor itraconazole using individual coupled whole-body physiologically-based pharmacokinetic (WB-PBPK) models
por: Vossen, Michaela, et al.
Publicado: (2007)

Cannot write session to /tmp/vufind_sessions/sess_sjitj742mi16rgehq4k4pkbjq1